OXB logo

Oxford Biomedica Share Price

Symbol: LSE:OXBMarket Cap: UK£467.8mCategory: Pharmaceuticals & Biotech

OXB Share Price Performance

UK£4.41
0.90 (25.50%)
13.2% undervalued intrinsic discount
UK£5.08
Fair Value
UK£4.41
0.90 (25.50%)
13.2% undervalued intrinsic discount
UK£5.08
Fair Value
Price UK£4.41
AnalystConsensusTarget UK£5.08

OXB Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget·Updated
Fair Value UK£5.08 13.2% undervalued intrinsic discount

CDMO Expansion Will Widen Global Cell And Gene Therapy Access

0users have liked this narrative
0users have commented on this narrative
20users have followed this narrative

Recent OXB News & Updates

No updates

Oxford Biomedica plc Key Details

UK£128.8m

Revenue

UK£75.8m

Cost of Revenue

UK£53.0m

Gross Profit

UK£96.2m

Other Expenses

-UK£43.2m

Earnings

Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
Sep 23, 2025
Earnings per share (EPS)
-0.41
Gross Margin
41.17%
Net Profit Margin
-33.53%
Debt/Equity Ratio
66.2%

Oxford Biomedica plc Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About OXB

Founded
1996
Employees
850
CEO
Frank Mathias
WebsiteView website
www.oxb.com

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

U.K. Market Performance

  • 7 Days: 3.2%
  • 3 Months: 19.1%
  • 1 Year: 16.4%
  • Year to Date: 15.8%
The market has climbed 3.2% in the last 7 days, lead by the Financials sector with a gain of 2.7%. The market is up 16% over the last 12 months. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading